Matinas BioPharma (MTNB) Sees Large Volume Increase

Share on StockTwits

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) saw an uptick in trading volume on Friday . 3,791,485 shares traded hands during trading, an increase of 243% from the previous session’s volume of 1,105,858 shares.The stock last traded at $0.99 and had previously closed at $0.94.

Several research analysts have issued reports on the company. Maxim Group reiterated a “buy” rating and issued a $5.00 price objective on shares of Matinas BioPharma in a research report on Thursday. Zacks Investment Research upgraded Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Tuesday, April 16th. BTIG Research assumed coverage on Matinas BioPharma in a research report on Friday. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Roth Capital assumed coverage on Matinas BioPharma in a research report on Monday, February 11th. They issued a “buy” rating and a $4.75 price objective for the company.

Matinas BioPharma (NYSEAMERICAN:MTNB) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01).

A number of large investors have recently added to or reduced their stakes in MTNB. Renaissance Technologies LLC raised its position in Matinas BioPharma by 325.6% in the third quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $124,000 after acquiring an additional 103,200 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Matinas BioPharma in the fourth quarter valued at $39,000. IFP Advisors Inc increased its position in shares of Matinas BioPharma by 222.0% in the fourth quarter. IFP Advisors Inc now owns 1,775,000 shares of the company’s stock valued at $1,083,000 after buying an additional 1,223,828 shares in the last quarter. BlackRock Inc. increased its position in shares of Matinas BioPharma by 147.1% in the fourth quarter. BlackRock Inc. now owns 290,589 shares of the company’s stock valued at $173,000 after buying an additional 173,005 shares in the last quarter. Finally, Private Advisor Group LLC increased its position in shares of Matinas BioPharma by 100.4% in the fourth quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after buying an additional 24,978 shares in the last quarter.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Equities Focus and is owned by of Equities Focus. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.equitiesfocus.com/2019/05/17/matinas-biopharma-mtnb-sees-large-volume-increase.html.

Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Featured Story: What is the Bid-Ask Spread?

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.